All articles tagged with #rheumatoid arthritis
New Semmelweis University research suggests persistent rheumatoid arthritis symptoms may be driven by sleep disorders, depression, obesity, and smoking even when inflammation is controlled, prompting a model to identify non-inflammatory drivers and guide personalized treatment, with AI-driven subgroups as future work.
A 1985 death of a baby in the hands of neurosurgeon Kevin Tracey propelled him to study inflammation, culminating in the FDA-approved SetPoint System—a small neck implant that stimulates the vagus nerve for one minute daily to dampen inflammation in rheumatoid arthritis patients, offering dramatic relief for many while facing ongoing insurance denials; Tracey sees this as the dawn of bioelectronic medicine and a potential path to other inflammatory diseases.
Rheumatoid arthritis is an autoimmune disease marked by joint pain, morning stiffness, swelling, and fatigue; early diagnosis and treatment with DMARDs and biologics, along with physical therapy, regular movement, sleep, stress management, and an anti-inflammatory diet, can slow progression and protect joints, though symptoms can wax and wane and may include mood changes and other systemic effects.
A Nature Immunology study using spatial transcriptomics reveals that persistent scar formation (fibrosis) and disrupted fibroblast–endothelial signaling in RA joints may drive treatment resistance even when inflammation is controlled, pointing to a new fibrosis-focused therapeutic target for patients who don’t respond to standard therapies.
Obakulactone (OL), a natural compound from Phellodendri cortex, promotes degradation of ACOT1 via the ubiquitin–proteasome system, restoring unsaturated fatty acid balance and reducing inflammation in a rat model of rheumatoid arthritis. The study reported OL lowered inflammatory cytokines and autoantibody markers, shifted macrophages toward anti-inflammatory states, and inhibited synovial fibroblast growth, with direct ACOT1 binding (Kd ~6 μM), suggesting a novel metabolic-targeted approach for RA treatment.
A long-term analysis from King’s College London shows that a 12-month course of abatacept in people at high risk of rheumatoid arthritis can delay disease onset by up to four years, with benefits persisting after treatment ends; strongest effects were in those at highest risk identified by specific autoantibodies, and while the therapy does not permanently prevent RA, early immune modulation may lessen future symptom burden and support preventive strategies, with safety comparable to placebo.
A Flinders University–led study finds methotrexate, a long-used rheumatoid arthritis drug, lowers systolic blood pressure by about 7.4 mmHg in newly diagnosed RA patients compared with sulfasalazine, a reduction that could meaningfully reduce risk of heart attack and stroke. The blood-pressure drop did not track with improvements in joint symptoms or arterial stiffness, suggesting other pathways (such as reduced systemic inflammation) may be involved. Genetic factors may help predict who benefits most, paving the way for personalized therapy, though more research is needed.
Linda Green, 78, started regular exercise at 75 after moving to Ledian Gardens and, in three years, achieved a biological age of 51, improved strength, balance, metabolism and cardiovascular function, and was able to come off steroids for her 20‑year rheumatoid arthritis. She credits seven steps: start small; make exercise part of a routine; mix different activities; tailor training to you; track progress (via the building’s E-Gym); maintain balance with nutrition; and use exercise to rebuild confidence and social belonging. Her story shows it’s never too late to start and that guided programs and community support can transform health.
Rheumatoid arthritis has no cure, but researchers are identifying a preclinical window years before joint swelling to predict who will develop RA using autoantibodies (RF and anti-CCP) and clues from mucosal sites, and they’re testing preventive treatments in trials with immune drugs to delay or prevent the disease—though no approved prevention exists yet. Key challenges include accurately predicting progression and recruiting suitable participants.
A meta-analysis of 12 studies involving more than 270,000 adults found that following a healthy overall diet pattern—especially anti-inflammatory patterns like the Mediterranean diet and the Healthy Eating Index—is associated with a lower risk of developing rheumatoid arthritis. While not a guaranteed prevention or cure, consistent adherence to these eating patterns may reduce risk, potentially through reduced chronic inflammation and favorable effects on the microbiome. Consult a healthcare provider for personalized guidance.
Scientists have identified early, symptomless signs of rheumatoid arthritis, such as immune proteins and cell activity, which could lead to earlier diagnosis and prevention strategies, although treatments are still in development.
Scientists have discovered that rheumatoid arthritis (RA) begins years before symptoms appear, with changes in immune system profiles detectable in at-risk individuals. Elevated autoantibodies like ACPA and RF can predict RA development, but not all with these antibodies develop the disease. Recent research highlights immune system alterations, such as increased inflammatory proteins and activated B and T cells, in individuals before clinical symptoms emerge, offering potential for early detection and preventive therapies. These findings could lead to interventions that prevent or mitigate RA progression.
Lynn Milam's severe rheumatoid arthritis was dramatically improved by an FDA-approved nerve-stimulating implant that targets the vagus nerve, restoring her mobility and quality of life, and potentially offering a new treatment avenue for other autoimmune diseases.
The FDA has approved a device that uses electrical stimulation of the vagus nerve to reduce inflammation in rheumatoid arthritis patients, offering a new treatment option for those unresponsive to drugs, with promising results including pain relief and improved mobility.
Cassandra Smith, a woman with rheumatoid arthritis, experienced a life-changing improvement after using compounded GLP-1 medications for weight loss, which helped her reduce inflammation, eliminate flare-ups, and improve her overall quality of life, despite insurance not covering the drug.